

DOCKET NO.: ISIS-4976

PATENT 10/038335

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Ronnie C. Hanecak, Kevin P. Anderson, Clarence Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: MODULATION OF TELOMERE LENGTH BY OLIGONUCLEOTIDES

HAVING A G-CORE SEQUENCE

EXPRESS MAIL LABEL NO: EL568091723 US

DATE OF DEPOSIT: January 2, 2002

EL568091723US

Box	☐ Patent Application	Are - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 - 1886 -
	⊠ Sequence □ Design	
	ant Commissioner for Patents ngton, DC 20231	

Sir:

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find

Request for Nonpublication is attached.

×	A Utility Patent Application under 37 C.F.R. 1.53(b).		
	It is a continuing application, as follows:		
	\square continuation \square divisional \boxtimes continuation-in-part of prior application number $\underline{09/299,058}$.		
	A Design Patent Application (submitted in duplicate).		

Including the following:

\boxtimes	New o	New or Revised Specification, including pages 1 to 21 containing:		
	\boxtimes	Specification		
	\boxtimes	Claims		
	\boxtimes	Abstract		
		Substitute Specification, including Claims and Abstract.		
		The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.		
		The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.		
	includ matter for su	y of earlier application Serial NoFiled, ing Specification, Claims and Abstract (pages 1 - @@), to which no new has been added TOGETHER WITH a copy of the executed oath or declaration ch earlier application and all drawings and appendices. Such earlier application by incorporated into the present application by reference.		
	to Rel	e enter the following amendment to the Specification under the Cross-Reference ated Applications section (or create such a section): "This Application: a continuation of \Box is a divisional of \Box claims benefit of U.S. provisional cation Serial No filed		

	DOC	CKET NO. : ISIS-4976	- 3 -	PATENT		
		Signed Statement attached de	eleting inventor(s) named in th	e prior application.		
		A Preliminary Amendment.				
		Sheet of Formal Draw	wings.			
		☐ Drawing view to publish:				
		Petition to Accept Photograp	ohic Drawings.			
		☐ Petition Fee				
	×	An ☐ Executed ☑ Unexecuted Declaration or Oath and Power of Attorney.				
A Andread		An Associate Power of Attor	rney.			
		An \square Executed \square Copy of	f Executed Assignment of the I	nvention to		
		☐ A Recordation Fee		·		
	\boxtimes	The prior application is assig	gned of record to <u>ISIS Pharmac</u>	euticals, Inc.		
			U.S.C. § 119 of Patent Applica			
7	-	claimed: is enclosed.	each of the above applications prior application Serial No			
		Please enter the followater (or create such a sentential)	wing amendment to the first seence): "This application claims	entence of the specification s benefit of international		

\boxtimes	Applicant(s) by its/their undersigned attorney, claims small entity status under 37			
	C.F.R. §1.27 as:			
	an Independent Inventor			
	☑ a Small Business Concern			
	□ a Nonprofit Organization.			
	a Nonpront Organization.			
\boxtimes	Diskette Containing DNA/Amino Acid Sequence Information.			
\boxtimes	Statement to Support Submission of DNA/Amino Acid Sequence Information.			
×	Sequence listing consisting of pages1-3			
	The computer readable form in this application, is identical with that filed in Application Serial Number, filed In accordance with 37 CFR			
	1.821(e), please use the \square first-filed, \square last-filed or \square only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence			
	Listing is \square included in the originally-filed specification of the instant application,			
<u>.</u>	included in a separately filed preliminary amendment for incorporation into the specification.			
	Information Disclosure Statement.			
	Attached Form 1449.			
	Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.			
	A copy of Petition for Extension of Time as filed in the prior case.			
	Appended Material as follows:			
\boxtimes	Return Receipt Postcard (should be specifically itemized).			

INDEP. CLAIMS

DEPENDENT CLAIM

ADDITIONAL FILING FEE

TOTAL FILING FEE DUE

DOC	KET NO.	: ISIS-4976		- 5 -			PATENT
	Other as	s follows:					
FEE (CALCUL	ATION:					
	calculat	in this applicating the filing to gurposes.)					olication before st be retained
888	*****	********	*****	SMAL	L ENTITY	NOT SM	ALL ENTITY
888	****			RATE	FEE	RATE	FEE
DESIC	3N APPLICA	TION		\$165.00	\$0	\$330.00	\$
UTILI	UTILITY APPLICATIONS BASE FEE			\$370.00	\$370	\$740.00	\$
CALC	TY APPLICA CULATED AINDMENTS	ATION; ALL CLA FTER ENTRY OF	IMS ALL				
		No. Filed	No. Extra	*******			
P-7-1	OTAL CLAIMS	13- 20 =	0	\$9 each	\$0	\$18 each	\$

4-3=

FIRST PRESENTATION OF MULTIPLE

1

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

\$42 each

\$140

\$42

\$0

\$0

\$412

	The foregoing	amount due.
--	---------------	-------------

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

\$

\$

\$84 each

\$280

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 2 JANUARY 2002

Paul K. Legaard

Registration No. 38,534

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

©2001 WW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Ronnie C. Hanecak, Kevin P. Anderson, Clarence Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt

Serial No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filing Date: Herewith

Examiner: Not Yet Assigned

For: MODULATION OF TELOMERE LENGTH BY OLIGONUCLEOTIDES

HAVING A G-CORE SEQUENCE

EXPRESS MAIL LABEL NO: EL568091723 US DATE OF DEPOSIT: January 2, 2002

BOX SEQUENCE

Assistant Commissioner for Patents Washington DC 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

\bowtie	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

DOC	KET NO.: ISIS-4976	- 2 -	PATENT
	· ·		nter readable form, submitted in al data to that originally filed.
Date:	2 JANUARY 2:02	Paul K. Lega	K fay

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

58-3439 © 2001 WW

Registration No. 38,534